Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DCT002
MIFTS: 57

Ductal Carcinoma in Situ

Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ductal Carcinoma in Situ

About this section

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 12 29 15
Noninfiltrating Intraductal Carcinoma 73

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060074
UMLS 73 C0007124
Sources

Summaries for Ductal Carcinoma in Situ

About this section
Disease Ontology : 12 A breast carcinoma in situ characterized by abnormal cells in the lining of a breast duct.

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and in situ carcinoma. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Doxorubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related phenotypes are growth/size/body region and cellular

Wikipedia : 76 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Sources

Related Diseases for Ductal Carcinoma in Situ

About this section

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.6 ERBB2 ESR1
2 in situ carcinoma 31.4 BRCA1 CDH1 EGFR ERBB2 ESR1 KRT14
3 breast reconstruction 30.9 BRCA1 BRCA2
4 gynecomastia 30.5 AR CYP19A1 ESR1 PGR
5 mammographic density 30.4 CYP19A1 ESR1 PGR
6 breast ductal carcinoma 30.4 AR BRCA1 CCND1 CDH1 EGFR ERBB2
7 lobular neoplasia 30.3 BRCA1 CDH1 ERBB2 ESR1 MUC1
8 papillary carcinoma 30.1 CDH1 ERBB2 MUC1 PGR
9 papilloma 30.1 CCND1 KRT14 KRT5 KRT8 TP53
10 bilateral breast cancer 30.0 BRCA1 BRCA2 ERBB2 PGR
11 breast fibroadenoma 29.9 CYP19A1 ERBB2 ESR1 KRT14 KRT8 MKI67
12 breast disease 29.6 BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 KRT5
13 squamous cell carcinoma 28.9 AKT1 CCND1 CDH1 EGFR ERBB2 MKI67
14 breast cancer 28.0 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
15 breast apocrine carcinoma in situ 11.2
16 intracystic papillary adenoma 10.4 ERBB2 PGR
17 scirrhous adenocarcinoma 10.4 ERBB2 PGR
18 vestibular gland benign neoplasm 10.4 ESR1 PGR
19 vulvar benign neoplasm 10.4 ESR1 PGR
20 breast apocrine carcinoma 10.4 ERBB2 PGR
21 trigonitis 10.4 ESR1 PGR
22 vulvar syringoma 10.4 ESR1 PGR
23 lung leiomyoma 10.4 ESR1 PGR
24 vulvar leiomyoma 10.4 ESR1 PGR
25 bartholin's gland adenoma 10.4 ESR1 PGR
26 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
27 endometrium carcinoma in situ 10.4 PGR TP53
28 rare adenocarcinoma of the breast 10.3 AKT1 TP53
29 breast intraductal proliferative lesion 10.3 EGFR ERBB2
30 breast papillomatosis 10.3 CCND1 ERBB2
31 protoplasmic astrocytoma 10.3 PTGS2 TP53
32 mixed cell type cancer 10.3 ERBB2 PGR TP53
33 hereditary site-specific ovarian cancer syndrome 10.3 BRCA1 BRCA2
34 cerebral convexity meningioma 10.3 CDH1 TP53
35 intraductal papilloma 10.3
36 bartholin's duct cyst 10.3 AR TP53
37 supratentorial cancer 10.3 AKT1 EGFR TP53
38 central nervous system cancer 10.3 AKT1 EGFR TP53
39 cerebrum cancer 10.3 AKT1 EGFR TP53
40 glassy cell carcinoma of the cervix 10.3 ERBB2 ESR1 PGR
41 breast mucoepidermoid carcinoma 10.2 MUC1 PGR
42 breast osteosarcoma 10.2 ERBB2 KRT8
43 esophagus adenocarcinoma 10.2 ERBB2 PTGS2 TP53
44 soft tissue sarcoma 10.2 EGFR MKI67 TP53
45 leukocyte disease 10.2 AKT1 CCND1 TP53
46 barrett's adenocarcinoma 10.2 ERBB2 PTGS2 TP53
47 inverted papilloma 10.2 CCND1 MKI67 TP53
48 penile cancer 10.2 CCND1 EGFR TP53
49 calcifying epithelial odontogenic tumor 10.2 KRT8 TP53
50 bile duct cancer 10.2 CCND1 EGFR TP53

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ
Sources

Symptoms & Phenotypes for Ductal Carcinoma in Situ

About this section

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.48 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2 cellular MP:0005384 10.46 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
3 homeostasis/metabolism MP:0005376 10.46 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
4 digestive/alimentary MP:0005381 10.44 AR BRCA1 BRCA2 CCND1 CDH1 CYP19A1
5 integument MP:0010771 10.44 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
6 cardiovascular system MP:0005385 10.43 AKT1 AR BRCA1 CCND1 CDH1 CYP19A1
7 endocrine/exocrine gland MP:0005379 10.43 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
8 hematopoietic system MP:0005397 10.41 AKT1 AR BRCA1 BRCA2 CCND1 CLDN7
9 behavior/neurological MP:0005386 10.4 AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
10 mortality/aging MP:0010768 10.4 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
11 immune system MP:0005387 10.39 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
12 embryo MP:0005380 10.37 AKT1 AR BRCA1 BRCA2 CDH1 EGFR
13 adipose tissue MP:0005375 10.28 AKT1 AR BRCA1 CYP19A1 EGFR ESR1
14 neoplasm MP:0002006 10.27 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
15 normal MP:0002873 10.21 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
16 limbs/digits/tail MP:0005371 10.18 AR BRCA1 BRCA2 EGFR ERBB2 ESR1
17 muscle MP:0005369 10.18 AKT1 AR BRCA1 CYP19A1 EGFR ERBB2
18 nervous system MP:0003631 10.17 AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
19 craniofacial MP:0005382 10.15 AR CCND1 EGFR ERBB2 KRT14 KRT5
20 liver/biliary system MP:0005370 10.11 AKT1 AR CYP19A1 EGFR ESR1 KRT8
21 reproductive system MP:0005389 10.03 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
22 no phenotypic analysis MP:0003012 10.01 CDH1 EGFR ESR1 KRT5 MKI67 PGR
23 renal/urinary system MP:0005367 9.86 AR BRCA1 CLDN7 CYP19A1 EGFR ESR1
24 pigmentation MP:0001186 9.8 AR BRCA1 CYP19A1 EGFR KRT14 TP53
25 respiratory system MP:0005388 9.61 AKT1 BRCA1 CCND1 EGFR ERBB2 ESR1
26 skeleton MP:0005390 9.4 AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
Sources

Drugs & Therapeutics for Ductal Carcinoma in Situ

About this section

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 6055-19-2, 50-18-0 2907
3
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2 114977-28-5 148124
4
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
5
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
6 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
10 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
11 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2
12 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Alkylating Agents Phase 4,Phase 3,Phase 2
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
15
Tamoxifen Approved Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
16
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
17
Carboplatin Approved Phase 2, Phase 3,Phase 3 41575-94-4 10339178 38904 498142
18
Progesterone Approved, Vet_approved Phase 3,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
19
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 441203 84093
20
mometasone furoate Approved, Vet_approved Phase 3 83919-23-7
21
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
22
leucovorin Approved Phase 3 58-05-9 6006 143
23
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
24
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
25
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
26
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
27
Letrozole Approved, Investigational Phase 3,Phase 2,Not Applicable 112809-51-5 3902
28
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
29
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
30
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
31
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
32
Pertuzumab Approved Phase 3,Phase 2,Phase 1 145040-37-5, 380610-27-5 2540
33
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
34
Metformin Approved Phase 3 657-24-9 14219 4091
35
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
36
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
37
Lenograstim Approved, Investigational Phase 3 135968-09-1
38
Adenosine Approved, Investigational Phase 3 58-61-7 60961
39
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
41
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2,Not Applicable 388082-78-8, 231277-92-2 208908 9941095
42 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
44 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
45 Aromatase Inhibitors Phase 3,Phase 2,Not Applicable
46 Steroid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
47 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
48 Hormones Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 249)
# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 An Open-label, Multi-center Phase â…£ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer Completed NCT01660542 Phase 4 Neoadjuvant Chemotherapy with Docetaxel
4 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
5 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
6 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
7 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
8 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
9 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
10 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
11 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
12 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
13 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
14 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
15 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed NCT00038467 Phase 3 Tamoxifen;Exemestane
16 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed NCT00036270 Phase 3 exemestane (Aromasin);tamoxifen + exemestane
17 BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer Completed NCT00528567 Phase 3 Bevacizumab;Standard adjuvant chemotherapy
18 Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer Completed NCT02980965 Phase 3 letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
19 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
20 Management of Low-risk DCIS Recruiting NCT02492607 Phase 3
21 CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer Recruiting NCT02918084 Phase 3 Anastrozole or Letrozole or Exemestane;Anastrozole or Letrozole or Exemestane
22 Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer Recruiting NCT03150576 Phase 2, Phase 3 Olaparib;Paclitaxel and Carboplatin
23 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
24 A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients Recruiting NCT03561740 Phase 3 capecitabine
25 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
26 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
27 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
28 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
29 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
30 APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer Active, not recruiting NCT00402519 Phase 3
31 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
32 Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients Active, not recruiting NCT02772731 Phase 3
33 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Active, not recruiting NCT01358877 Phase 3 5-Fluorouracil;Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Pertuzumab;Placebo;Trastuzumab
34 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
35 A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Active, not recruiting NCT01566721 Phase 3 Herceptin
36 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting NCT03036488 Phase 3 Carboplatin;Paclitaxel;Doxorubicin;Epirubicin;Cyclophosphamide;Placebo
37 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Active, not recruiting NCT00878709 Phase 3 neratinib
38 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Active, not recruiting NCT01966471 Phase 3 Trastuzumab Emtansine;Trastuzumab;Pertuzumab;Paclitaxel;Epirubicin;Doxorubicin;Docetaxel;Cyclophosphamide;5-Fluorouracil
39 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
40 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
41 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting NCT01772472 Phase 3 trastuzumab;trastuzumab emtansine
42 Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer Enrolling by invitation NCT03580395 Phase 2, Phase 3 Apatinib;paclitaxel;cisplatin
43 The LightPath® and 68Ga-RM2 in Breast Cancer Study Not yet recruiting NCT03731026 Phase 3 68Ga-RM2
44 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
45 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
46 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
47 Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
48 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2 Neoadjuvant Cisplatin Chemotherapy
49 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
50 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel

Search NIH Clinical Center for Ductal Carcinoma in Situ

Sources

Genetic Tests for Ductal Carcinoma in Situ

About this section

Genetic tests related to Ductal Carcinoma in Situ:

# Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 29
Sources

Anatomical Context for Ductal Carcinoma in Situ

About this section

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

41
Breast, Lymph Node, Testes, Bone, Skin, Ovary, Prostate
Sources

Publications for Ductal Carcinoma in Situ

About this section

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 1331)
# Title Authors Year
1
Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients. ( 30322671 )
2019
2
Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. ( 29955142 )
2018
3
The PPARI^ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. ( 29350308 )
2018
4
Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis. ( 29973218 )
2018
5
Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. ( 29759643 )
2018
6
Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. ( 29398498 )
2018
7
Magnetic resonance imaging findings of high-grade ductal carcinoma in situ of the male breast: A case report. ( 29977557 )
2018
8
Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ. ( 29428007 )
2018
9
Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. ( 29383628 )
2018
10
The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study. ( 29417425 )
2018
11
Development of a Model to Predict Invasiveness in Ductal Carcinoma In Situ Diagnosed by Percutaneous Biopsy-Original Study and Critical Evaluation of the Literature. ( 29798815 )
2018
12
Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ. ( 29632058 )
2018
13
Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery? ( 29773535 )
2018
14
Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis. ( 29593431 )
2018
15
Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy. ( 29271113 )
2018
16
Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. ( 29439886 )
2018
17
Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ-Reply. ( 29344613 )
2018
18
A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. ( 29445939 )
2018
19
Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series. ( 29322827 )
2018
20
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. ( 29394917 )
2018
21
Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. ( 29730730 )
2018
22
Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. ( 29786772 )
2018
23
Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data. ( 29669162 )
2018
24
Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ. ( 29344621 )
2018
25
Factors associated with the increasing trend of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ: Analysis of Surveillance, Epidemiology, and End Results data. ( 29804045 )
2018
26
Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. ( 29398324 )
2018
27
Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery. ( 29709458 )
2018
28
Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ. ( 29694611 )
2018
29
A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk. ( 30054280 )
2018
30
Functional Role of microRNAs in the Progression of Breast Ductal Carcinoma in situ. ( 30273605 )
2018
31
Morphologic and Molecular Features of Breast Ductal Carcinoma In Situ. ( 30385094 )
2018
32
Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). ( 30410060 )
2018
33
Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. ( 30429518 )
2018
34
Possible predictive role of cancer/testis antigens in breast ductal carcinoma in situ. ( 30546463 )
2018
35
Breast-conserving therapy for primary Ductal Carcinoma in Situ in The Netherlands: A multi-center study and population-based analysis. ( 30118902 )
2018
36
Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study. ( 30121548 )
2018
37
Case Report: Ductal Carcinoma in Situ Within A Granulomatous Mastitis. ( 30123886 )
2018
38
Ductal carcinoma in-situ, cystic hypersecretory type presented by recurrent hemorrhagic cyst. ( 30124440 )
2018
39
IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression. ( 30134951 )
2018
40
Modeling Human Ductal Carcinoma In Situ in the Mouse. ( 30145750 )
2018
41
Accuracy of Breast Magnetic Resonance Imaging Compared to Mammography in the Preoperative Detection and Measurement of Pure Ductal Carcinoma In Situ: A Retrospective Analysis. ( 30149976 )
2018
42
Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial interobserver concordance. ( 30168167 )
2018
43
Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS. ( 30190195 )
2018
44
Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence. ( 30194658 )
2018
45
Clinical Trials for Ductal Carcinoma In Situ of the Breast. ( 30206737 )
2018
46
Differential Expression of Cancer-Associated Fibroblast-Related Proteins in Ductal Carcinoma in situ According to Molecular Subtype and Stromal Histology. ( 30223270 )
2018
47
Partial breast irradiation for ductal carcinoma in situ: The Goldilocks principle? ( 30230142 )
2018
48
Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. ( 30236106 )
2018
49
Clinical presentation of ductal carcinoma in situ of breast with intraluminal crystalloids: Radiologic-histologic correlation. ( 30241034 )
2018
50
Ductal carcinoma in situ current trends, controversies, and review of literature. ( 30244816 )
2018
Sources

Variations for Ductal Carcinoma in Situ

About this section

Cosmic variations for Ductal Carcinoma in Situ:

9 (show all 44)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6005476 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 9
2 COSM10656 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 9
3 COSM10662 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 9
4 COSM10701 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.824G>T p.C275F 17:7673796-7673796 9
5 COSM10867 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 17:7673823-7673823 9
6 COSM44415 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 9
7 COSM44737 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.860A>G p.E287G 17:7673760-7673760 9
8 COSM6932 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 9
9 COSM10779 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 9
10 COSM43559 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 17:7675095-7675095 9
11 COSM43714 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.836G>A p.G279E 17:7673784-7673784 9
12 COSM44901 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 17:7675080-7675080 9
13 COSM10660 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 17:7673802-7673802 9
14 COSM43814 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 9
15 COSM11089 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 9
16 COSM6906973 SMARCA4 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 9
17 COSM6906974 PPP2R1A breast,NS,carcinoma in situ,ductal carcinoma in situ c.510C>A p.F170L 19:52212692-52212692 9
18 COSM775 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>G p.H1047R 3:179234297-179234297 9
19 COSM12458 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 3:179218304-179218304 9
20 COSM776 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>T p.H1047L 3:179234297-179234297 9
21 COSM760 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1624G>A p.E542K 3:179218294-179218294 9
22 COSM774 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3139C>T p.H1047Y 3:179234296-179234296 9
23 COSM763 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1633G>A p.E545K 3:179218303-179218303 9
24 COSM754 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1035T>A p.N345K 3:179203765-179203765 9
25 COSM580 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.181C>A p.Q61K 1:114713909-114713909 9
26 COSM565 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>C p.G12A 1:114716126-114716126 9
27 COSM6057047 NOTCH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.7372C>T p.P2458S 9:136496367-136496367 9
28 COSM6005481 MAP2K2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.931G>T p.D311Y 19:4097332-4097332 9
29 COSM521 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 12:25245350-25245350 9
30 COSM516 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.34G>T p.G12C 12:25245351-25245351 9
31 COSM532 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.38G>A p.G13D 12:25245347-25245347 9
32 COSM520 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>T p.G12V 12:25245350-25245350 9
33 COSM1179671 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.925C>T p.P309S 7:152273792-152273792 9
34 COSM4595028 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.2681G>A p.R894Q 7:152235905-152235905 9
35 COSM6057048 HRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.148A>G p.T50A 11:533908-533908 9
36 COSM6906971 H3F3A breast,NS,carcinoma in situ,ductal carcinoma in situ c.218G>A p.R73Q 1:226065745-226065745 9
37 COSM48358 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.929C>T p.S310F 17:39711955-39711955 9
38 COSM14060 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2264T>C p.L755S 17:39723967-39723967 9
39 COSM19786 CDH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 16:68810288-68810288 9
40 COSM6057049 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.61A>G p.T21A 14:104780202-104780202 9
41 COSM33765 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.49G>A p.E17K 14:104780214-104780214 9
42 COSM5174142 breast,NS,carcinoma in situ,ductal carcinoma in situ c.884C>T p.S295F 17:39711955-39711955 9
43 COSM6906972 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 9
44 COSM6964823 breast,NS,carcinoma in situ,ductal carcinoma in situ c.659C>T p.T220M 1:39897898-39897898 9
Sources

Expression for Ductal Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Ductal Carcinoma in Situ.
Sources

Pathways for Ductal Carcinoma in Situ

About this section

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.9 AKT1 BRCA1 CCND1 CDH1 EGFR ERBB2
2
GPCR Pathway 64
Show member pathways
 13.76 AKT1 BRCA1 BRCA2 CCND1 EGFR ERBB2
3
Cytokine Signaling in Immune system 66
Show member pathways
 13.39 AKT1 CCND1 EGFR ERBB2 MUC1 PTGS2
4
PI3K-Akt signaling pathway 37
Show member pathways
 13.02 AKT1 BRCA1 CCND1 EGFR ERBB2 PTGS2
5
Endometrial cancer 37
Show member pathways
 12.8 AKT1 AR BRCA2 CCND1 CDH1 EGFR
6
Development HGF signaling pathway 22
Show member pathways
 12.75 AKT1 CDH1 ERBB2 ESR1 PTGS2 TP53
7
Chks in Checkpoint Regulation 64
Show member pathways
 12.73 BRCA1 BRCA2 CCND1 ESR1 TP53
8
Glioma 37
Show member pathways
 12.58 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
9
Pathways in cancer 37
12.58 AKT1 AR BRCA2 CCND1 CDH1 EGFR
10
DNA Damage 4
12.56 BRCA1 BRCA2 CCND1 MKI67 TP53
11
ErbB signaling pathway 1 37
Show member pathways
 12.52 AKT1 CCND1 EGFR ERBB2 TP53
12
MicroRNAs in cancer 37
12.51 BRCA1 CCND1 EGFR ERBB2 PTGS2 TP53
13
Apoptosis Pathway 72
Show member pathways
 12.47 AKT1 EGFR ERBB2 TP53
14
WNT Signaling 64
12.46 AKT1 CCND1 CDH1 PTGS2 TP53
15
Development EGFR signaling pathway 22
Show member pathways
 12.46 AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
16
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.43 AKT1 BRCA1 ESR1 PTGS2
17
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.33 AKT1 CCND1 EGFR ERBB2 ESR1 PTGS2
18
Gastric cancer 37
Show member pathways
 12.32 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
19
p53 Signaling 64
Show member pathways
 12.29 AKT1 BRCA1 CCND1 TP53
20
Cell cycle Role of SCF complex in cell cycle regulation 22
Show member pathways
 12.27 BRCA1 CCND1 ESR1 PGR
21
Proteoglycans in cancer 37
12.26 AKT1 CCND1 EGFR ERBB2 ESR1 TP53
22
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.23 AKT1 CCND1 EGFR ERBB2 TP53
23
AKT Signaling Pathway 67
12.16 AKT1 CCND1 EGFR ERBB2 TP53
24
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12.13 AKT1 AR CCND1 EGFR ERBB2
25
Hepatitis C 37
12.12 AKT1 CLDN7 EGFR TP53
26
Signaling by PTK6 66
Show member pathways
 12.11 AKT1 CCND1 EGFR ERBB2
27
MAPK Pathway 72
Show member pathways
 12.08 AKT1 EGFR ERBB2 TP53
28
Spinal Cord Injury 1
12.06 CCND1 EGFR PTGS2 TP53
29
Colorectal Cancer Metastasis 64
12.06 AKT1 CCND1 CDH1 EGFR PTGS2 TP53
30
Cell cycle Cell cycle (generic schema) 22
Show member pathways
 12.03 AKT1 CCND1 CDH1 PTGS2 TP53
31
Thyroid hormone signaling pathway 37
12.03 AKT1 CCND1 ESR1 TP53
32
DNA Damage Response (only ATM dependent) 1
12.02 AKT1 CCND1 ERBB2 TP53
33
Glioblastoma Multiforme 64
12 AKT1 CCND1 EGFR TP53
34
Interleukin-4 and 13 signaling 66
12 AKT1 CCND1 MUC1 PTGS2 TP53
35
Signaling by ERBB4 66
Show member pathways
 11.98 EGFR ERBB2 ESR1 PGR
36
Small cell lung cancer 37
11.91 AKT1 CCND1 PTGS2 TP53
37
Nuclear Receptor transcription pathway 66
Show member pathways
 11.88 AR ESR1 PGR
38
Androgen receptor signaling pathway 1
11.85 AKT1 AR BRCA1 CCND1 EGFR
39
BRCA1 Pathway 64
Show member pathways
 11.84 BRCA1 BRCA2 TP53
40
Glucocorticoid receptor regulatory network 1
11.84 AKT1 KRT14 KRT5 TP53
41
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.81 AR CCND1 CDH1
42
Regulation of nuclear SMAD2/3 signaling 1
11.8 AKT1 AR ESR1
43
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.78 AKT1 KRT8 MKI67
44
Platinum drug resistance 37
11.78 AKT1 BRCA1 ERBB2 TP53
45
Adherens junction 37
11.77 CDH1 EGFR ERBB2
46
Transcription Ligand-dependent activation of the ESR1/SP pathway 22
Show member pathways
 11.75 CCND1 EGFR ESR1
47
Association Between Physico-Chemical Features and Toxicity Associated Pathways 1
11.74 AKT1 EGFR ERBB2
48
Pathways Affected in Adenoid Cystic Carcinoma 1
11.73 AKT1 BRCA1 ERBB2 TP53
49
Regulation of Telomerase 1
11.72 AKT1 CCND1 EGFR ESR1
50
Central carbon metabolism in cancer 37
11.71 AKT1 EGFR ERBB2 TP53
Sources

GO Terms for Ductal Carcinoma in Situ

About this section

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.89 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2 nuclear chromatin GO:0000790 9.56 AR ESR1 MUC1 TP53
3 protein-containing complex GO:0032991 9.23 AKT1 AR BRCA1 BRCA2 EGFR ESR1
4 nucleus GO:0005634 10.06 AKT1 AR BRCA1 BRCA2 CCND1 EGFR

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 protein deubiquitination GO:0016579 9.98 AR BRCA1 ESR1 TP53
2 positive regulation of protein phosphorylation GO:0001934 9.89 AKT1 CCND1 EGFR ERBB2
3 cytokine-mediated signaling pathway GO:0019221 9.88 AKT1 CCND1 MUC1 PTGS2 TP53
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.87 AR CCND1 ESR1 PGR
5 positive regulation of transcription, DNA-templated GO:0045893 9.86 AKT1 AR BRCA1 BRCA2 CDH1 EGFR
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 AKT1 EGFR PTGS2
7 positive regulation of cell growth GO:0030307 9.84 AKT1 EGFR ERBB2
8 cellular response to mechanical stimulus GO:0071260 9.83 AKT1 EGFR PTGS2
9 response to estrogen GO:0043627 9.81 BRCA1 CCND1 ESR1
10 cellular response to growth factor stimulus GO:0071363 9.78 AKT1 EGFR ERBB2
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 AKT1 EGFR PTGS2
12 steroid hormone mediated signaling pathway GO:0043401 9.75 AR ESR1 PGR
13 epidermis development GO:0008544 9.73 EGFR KRT14 KRT5 S100A7
14 cellular response to epidermal growth factor stimulus GO:0071364 9.72 AKT1 EGFR ERBB2
15 response to estradiol GO:0032355 9.72 BRCA2 CCND1 EGFR ESR1 PTGS2
16 response to organic substance GO:0010033 9.71 AKT1 CCND1 CDH1 PTGS2
17 cell proliferation GO:0008283 9.7 AKT1 AR BRCA2 EGFR ERBB2 MKI67
18 mammary gland development GO:0030879 9.69 BRCA2 CYP19A1 PGR
19 hemidesmosome assembly GO:0031581 9.67 KRT14 KRT5
20 Leydig cell differentiation GO:0033327 9.66 AR CCND1
21 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.66 ESR1 TP53
22 positive regulation of transcription by RNA polymerase III GO:0045945 9.65 AR ERBB2
23 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.64 EGFR TP53
24 mitotic G1 DNA damage checkpoint GO:0031571 9.63 CCND1 TP53
25 positive regulation of vasoconstriction GO:0045907 9.63 AKT1 EGFR PTGS2
26 obsolete positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.62 AKT1 EGFR
27 prostate gland growth GO:0060736 9.61 AR CYP19A1
28 negative regulation of ERBB signaling pathway GO:1901185 9.58 EGFR ERBB2
29 cellular response to indole-3-methanol GO:0071681 9.56 BRCA1 CDH1
30 chordate embryonic development GO:0043009 9.54 BRCA1 BRCA2
31 mammary gland alveolus development GO:0060749 9.54 AR CCND1 ESR1
32 morphogenesis of an epithelial fold GO:0060571 9.52 AR EGFR
33 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.49 AR PGR
34 response to UV-A GO:0070141 9.13 AKT1 CCND1 EGFR
35 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 BRCA1 BRCA2 MUC1 TP53
36 positive regulation of transcription by RNA polymerase II GO:0045944 10.17 AKT1 AR BRCA1 EGFR ESR1 PGR
37 cellular response to DNA damage stimulus GO:0006974 10.04 AKT1 BRCA1 BRCA2 CCND1 TP53
38 positive regulation of gene expression GO:0010628 10.03 AKT1 AR BRCA1 ERBB2 TP53

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.97 AR BRCA1 ESR1 PGR S100A7 TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.88 AR ESR1 MUC1 PGR TP53
3 protein kinase binding GO:0019901 9.85 AKT1 CCND1 EGFR ESR1 TP53
4 beta-catenin binding GO:0008013 9.71 AR CDH1 ESR1
5 protein phosphatase binding GO:0019903 9.7 EGFR ERBB2 TP53
6 ATPase binding GO:0051117 9.69 AR ESR1 PGR
7 identical protein binding GO:0042802 9.65 AKT1 BRCA1 BRCA2 CDH1 CLDN7 EGFR
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 EGFR ERBB2 ESR1
9 steroid hormone receptor activity GO:0003707 9.58 AR ESR1 PGR
10 nuclear receptor activity GO:0004879 9.54 AR ESR1 PGR
11 steroid binding GO:0005496 9.5 AR ESR1 PGR
12 nitric-oxide synthase regulator activity GO:0030235 9.33 AKT1 EGFR ESR1
13 enzyme binding GO:0019899 9.28 AKT1 AR BRCA1 CCND1 EGFR ESR1
14 protein binding GO:0005515 10.23 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
Sources

Sources for Ductal Carcinoma in Situ

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....